Abstract Library

#2761 Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan

Introduction: Insulinomas are rare functional and benign neuroendocrine tumors of Pancreas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: Insulinoma, progression-free survival, sunitinib, malignant,

#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Werner T

Authors: Werner T, Riemer J, Dizdar L, Wolf A, Cupisti K,

Keywords: MTC, IAP, survivin, XIAP,

#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?

Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Grana C, Chiappa A, Biffi R,

Keywords: PNET, surgery, liver metastases, distal pancreatectomy, survival,

#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Grana C, Bodei L,

Keywords: neuroendocrine tumors, peptide receptor radionuclide therapy, surgery, survival, progression-free survival,

#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment

Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Falconi M, Spada F,

Keywords: pancreatic neuroendocrine tumor, synchronous liver metastases, debulking, resection, prognostic factors, survival,